Example: Heart Attack

Clinical Trials Sponsored by Amplyx Pharmaceuticals

Total 9 results

NCT05676034

Recruiting

AMX0035 in Adult Patients With Wolfram Syndrome

Wolfram Syndrome
NCT04987671

Active, not recruiting

Pharmacokinetic and Pharmacodynamic Study of AMX0035 in Patients With ALS

ALS
NCT05619783

Enrolling by invitation

Extension Study Evaluating The Safety And Tolerability of AMX0035

Amyotrophic Lateral Sclerosis
NCT04516096

Completed

A Compassionate Use Protocol of AMX0035 for Treatment of Patients With Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis
NCT05021536

Active, not recruiting

Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment (Phoenix)

Amyotrophic Lateral Sclerosis
NCT05286372

Approved for marketing

An Intermediate Size Expanded Access Protocol of AMX0035 for ALS

Amyotrophic Lateral Sclerosis
NCT03488524

Completed

Open Label Extension Study of AMX0035 in Patients With ALS (CENTAUR-OLE)

Amyotrophic Lateral Sclerosis | ALS
NCT03533257

Completed

Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's Disease (PEGASUS)

Alzheimer Disease
NCT03127514

Completed

AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS) (CENTAUR)

Central Nervous System Diseases | Nervous System Diseases | Neuromuscular Diseases | Neurodegenerative Diseases | Motor Neuron Disease | Amyotrophic Lateral Sclerosis | Spinal Cord Diseases | TDP-43 Proteinopathies